Invicto Labz

P—26 • Preclinical small-molecule profile

5-Amino-1MQ(Also known as 5-amino-1-methylquinolinium)

A concise educational overview of a small-molecule NNMT inhibitor studied in cellular and mouse models of metabolic dysfunction.

Name

5-Amino-1MQ

5-amino-1-methylquinolinium; often abbreviated 5A1MQ

Scientific classification
Membrane-permeable methylquinolinium small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT)
Library family
Metabolic
Research status
Preclinical; published evidence is primarily cellular and mouse research
Regulatory status
No FDA-approved 5-Amino-1MQ product or indication

Compound overview

A small-molecule research compound that inhibits NNMT.

5-Amino-1MQ is a synthetic small molecule, not a peptide. It is used in laboratory research to inhibit nicotinamide N-methyltransferase, an enzyme involved in nicotinamide metabolism.

Published studies have primarily examined cultured adipocytes and diet-induced-obesity mouse models. These findings do not establish efficacy, safety, pharmacology, or appropriate use in humans.

Mechanism under study

NNMT inhibition and cellular methyl-donor metabolism

Research examines how NNMT inhibition changes nicotinamide methylation and related metabolic pools in cells and animal models.

NNMT

Enzyme inhibition

5-Amino-1MQ inhibits NNMT, reducing conversion of nicotinamide to 1-methylnicotinamide in experimental systems.

NAD+

Nicotinamide metabolism

Preclinical work measures changes in NAD+ biology following NNMT inhibition.

SAM

Methyl-donor balance

Studies also examine S-adenosylmethionine and connected metabolic pathways in adipose and liver models.

Cellular and mouse-model findings cannot establish human benefit, safety, dose, or long-term effects.

Current research areas

Questions under investigation

  • NNMT enzyme activity
  • NAD+ and nicotinamide metabolism
  • S-adenosylmethionine biology
  • Adipocyte and liver metabolism
  • Replication and controlled human research

Evidence summary

Preclinical research findings

  • Cell studies: Early work reported NNMT inhibition and changes in metabolic markers in cultured adipocytes.
  • Mouse models: Studies evaluated body composition and metabolic outcomes in diet-induced-obesity models.
  • Liver research: Later preclinical work examined obesity-related liver pathology and metabolic dysfunction.
  • Evidence gap: Controlled human efficacy and safety have not been established.

The evidence is preclinical and should not be interpreted as proof of weight-loss, metabolic, or other health benefits in people.

Educational notice

Education, not usage guidance.

This profile is provided for scientific education only. It is not medical advice, weight-loss guidance, dosing information, or instructions for 5-Amino-1MQ use. The compound is supplied for laboratory research use only, and controlled human safety and efficacy have not been established.

← Return to the libraryExplore the Academy →